We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Antigen Test Boosts Detection of Primary Biliary Cirrhosis

By LabMedica International staff writers
Posted on 30 Jun 2010
Print article
A new enzyme-linked immunosorbent assay (ELISA) significantly increases the serological detection rate for primary biliary cirrhosis (PBC).

The assay, which is based on a designer recombinant fusion protein, provides unparalleled sensitivity for detection of autoantibodies against the mitochondrial antigen M2 (AMA-M2) in the diagnosis of primary PBC.

The novel fusion protein combines the immunogenic domains of all three relevant enzyme complexes (3E) of the M2 antigen, presenting them in a defined stoichiometric relationship. This designer antigen is used together with the classical target antigen native pyruvate dehydrogenase in the new EUROIMMUN (Luebeck, Germany) anti-M2-3E ELISA. The extended antigen spectrum and the resulting increase in diagnostic efficiency make the test a powerful new tool for PBC diagnostics.

In a study with 170 sera from clinically characterized PBC patients the new Anti-M2-3E ELISA demonstrated a 14% higher sensitivity than a conventional Anti-M2 ELISA.

The Anti-M2-3E ELISA is easy to perform and, like other EUROIMMUN ELISAs, can be fully automated on the company's Analyzer I and I-2P systems. These flexible instrument systems offer reliable automated processing of an extensive range of validated parameters for autoimmune diagnostics, infectious serology, and allergology.

PBC is an immune-mediated chronic inflammatory cholestatic liver disease of unknown etiology. Up to 94% of patients exhibit AMA-M2 and these constitute the most important serological marker. The majority of M2-specific autoantibodies are directed against the enzyme pyruvate dehydrogenase, and many commercial ELISAs are based solely on this main target antigen. However, 5-10% of patients exhibit only antibodies against the other two main autoantigens of the M2 complex, namely branched-chain 2-oxoacid dehydrogenase and oxoglutarate dehydrogenase, and are therefore not detected with conventional tests.

EUROIMMUN produces a wide range of reagents for medical laboratory diagnostics. The main focus is on test systems for antibodies in patient serum. These allow highly sensitive and specific diagnosis of autoimmune diseases, infectious diseases, and allergies.

Related Links:
EUROIMMUN


New
Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Newborn Screening Test
NeoMass AAAC 3.0
New
Gold Member
Syphilis Screening Test
VDRL Antigen MR

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.